Board of This Pharma Stock To Weigh 1:10 Stock Split, 1:1 Bonus Issue On Aug 22

Welcure Drugs & Pharmaceuticals Ltd (BSE: 524661) plans to earmark Rs 70-80 crore to found a state-of-the-art, cGMP-compliant research center dedicated solely to agro-pharmaceuticals. The allocation will support the creation of purpose-built laboratory spaces, dedicated pilot-scale production lines, next-generation analytical instrumentation, and a robust and integrated quality management system.

Facilities will be configured to fulfill prevailing cGMP criteria and will be structured in accordance with the US FDA's Botanical Drug Development guidance, thereby positioning the company to engage in global botanical and ayurvedic markets, contingent upon the receipt of requisite regulatory approvals.

In parallel, the company's Board of Directors will convene on August 28, 2025, to deliberate on the possibility of raising an aggregate of Rs 80 crore via a Qualified Institutional Placement (QIP) to be executed in one or multiple tranches. Net proceeds derived from the placement will be allocated to laboratory infrastructure and, to the extent permitted, to general corporate activities. The Board will also review and approve the requisite enabling resolutions, structure of the issue, and any necessary shareholder consents during the session.

In a parallel but distinct action, the Board is scheduled to convene on August 22, 2025, expressly to scrutinise a proposed stock split and a contemplated bonus issue, succeeding the significant Q1FY26 financial results released by the Company.

Welcure Drugs & Pharmaceuticals Limited reports that its Board of Directors will meet on Friday, August 22, 2025, to discuss the possibility of splitting equity shares in a 1:10 ratio and issuing bonus shares up to 1:1, or one bonus equity share for every equity share held, provided sufficient reserves are available and the necessary approvals are obtained.

"If both proposals are approved at the indicated ratios and implemented in either sequence, a shareholder holding 1 share pre-action would hold up to 20 shares postactions (1→10 via split, then 10→20 via 1:1 bonus, or vice-versa). There is no change in the shareholder's proportional ownership or aggregate value on the record date," said Welcure Drugs & Pharmaceuticals in a stock exchange filing.

In its recently released Q1FY26 results, Welcure reported exceptional growth, with the company's export-oriented sourcing services segment spearheading the performance. Revenues from operations reached Rs 299.91 crore, a considerable advance from Rs 21.21 crore posted in Q4FY25, reflecting an approximate sequential growth of 1,300 per cent.

Founded in 1992, Welcure Drugs & Pharmaceuticals is principally occupied with the manufacture and commercialisation of healthcare formulations, maintaining a disciplined emphasis on international compliance, uncompromising quality, and systematic global expansion. The company's recent strategic allocations to research and its ongoing capital reconstitution programs reflect a clear and sustained commitment to broadening competitive positioning and to delivering sustained growth in the longer term.